VDAC1 and hepatocellular carcinoma: Studies have shown that the VDAC1 inhibitor Novobiocin can reduce the mono-ubiquitination level of VDAC1 K274, and subsequent mutation of this site weakens the interaction between Hsp90α-VDAC1, increases the oligomerization of VDAC1, and thus affects the progression of HCC (120).